Nothing Special   »   [go: up one dir, main page]

Want et al., 2019 - Google Patents

Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer

Want et al., 2019

View PDF @Full View
Document ID
14687121533723051694
Author
Want M
Konstorum A
Huang R
Jain V
Matsueda S
Tsuji T
Lugade A
Odunsi K
Koya R
Battaglia S
Publication year
Publication venue
Oncoimmunology

External Links

Snippet

Ovarian cancer (OC) has an overall modest number of mutations that facilitate a functional immune infiltrate able to recognize tumor mutated antigens, or neoantigens. Although patient-derived xenografts (PDXs) can partially model the tumor mutational load and mimic …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Similar Documents

Publication Publication Date Title
Gide et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy
Wu et al. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Zheng et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing
Gunderson et al. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer
Van der Leun et al. CD8+ T cell states in human cancer: insights from single-cell analysis
Balan et al. Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity
Li et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy
Puig-Saus et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Meier et al. Bystander T cells in cancer immunology and therapy
Mognol et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells
Zheng et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers
Brownlie et al. Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood
Mei et al. Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response
Want et al. Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
Smith et al. Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes
Linette et al. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
Pai et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Van de Velde et al. Neuroblastoma formation requires unconventional CD4 T cells and arginase-1–dependent myeloid cells
Xiong et al. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM
Poran et al. Combined TCR repertoire profiles and blood cell phenotypes predict melanoma patient response to personalized neoantigen therapy plus anti-PD-1
Rodríguez-Hernández et al. Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID
Lee et al. Preferential infiltration of unique Vγ9Jγ2-Vδ2 T cells into glioblastoma multiforme
Yokoi et al. Identification of a unique subset of tissue-resident memory CD4+ T cells in Crohn’s disease
Purcarea et al. Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity
Baleeiro et al. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy